Dicerna Pharmaceuticals Inc. (DRNA) Undervalued by 24.17%

Publicly-traded company Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) had a closing price of $16.97 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $22.38, this means that the stock is underpriced by 24.17%. In the past 52 weeks the company’s stock price has moved within the range of $9.31 to $18.39.

This particular stock’s 5-day moving average is 16.57, its 20-day moving average is 15.73 and its 100-day moving average is 14.72. Dicerna Pharmaceuticals Inc. (DRNA) currently has 65.39M shares outstanding, which means that its market capitalization is $1.11B.

The Details: Dicerna Pharmaceuticals Inc. (DRNA) Financial Health

Return on Assets, which is expressed as a percentage, tells us how well a public company is using its assets to turn a profit. The larger the percentage, the better it is At the moment, Dicerna Pharmaceuticals Inc. Return on Assets is -26.20%.

What Does Wall Street Say about Company?

When selecting potential stocks to buy, many investors want to find out what Wall Street professionals are thinking about the company beforehand – like what the average analyst rating is. At the moment, the average analyst rating for DRNA is Buy. Out of 10 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 1 rated it an overweight, 0 rated it hold, and 9 rated it a Buy.

Understanding Profitability at Dicerna Pharmaceuticals Inc. (DRNA)

A good way of assessing a public company’s profitability is by looking at its Earnings per Share (EPS). In the most recent financial results released by Dicerna Pharmaceuticals Inc., for the quarter ending on 09/2019, the company posted EPS of -0.30. The average estimate of Wall Street analysts had projected -0.09.

Wall Street analysts, on average, are forecasting the company’s EPS to be -0.29, compared to -0.35 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 8 analysts is 11.06M.